Notably, Ridker et al. [15] demonstrated that rosuvastatin significantly reduced CV events and all-cause mortality in patients with moderate CKD and elevated high-sensitivity CRP, supporting its use in primary prevention for this subgroup. Here, CRP is linked to chronic kidney disease.